Abstract: One variation of a method for monitoring manufacture of assembly units includes: receiving selection of a target location hypothesized by a user to contain an origin of a defect in assembly units of an assembly type; accessing a feature map linking non-visual manufacturing features to physical locations within the assembly type; for each assembly unit, accessing an inspection image of the assembly unit recorded by an optical inspection station during production of the assembly unit, projecting the target location onto the inspection image, detecting visual features proximal the target location within the inspection image, and aggregating non-visual manufacturing features associated with locations proximal the target location and representing manufacturing inputs into the assembly unit based on the feature map; and calculating correlations between visual and non-visual manufacturing features associated with locations proximal the target location and the defect for the set of assembly units.

Abstract: The invention relates to a method for determining whether a subject has or is susceptible to developing a primary immunodeficiency (PID), the method comprising using a linear mixed model to fit a transcriptome profile of the subject to a PID prediction equation developed by fitting into a linear mixed model a transcriptomic relationship matrix generated from a reference set of transcriptome profiles of reference subjects with and without PID, wherein the prediction equation's result indicates whether the subject has or is susceptible to PID. The invention relates to a method for developing a primary immunodeficiency (PID) prediction equation for determining whether a subject has or is susceptible to developing a PID, the method comprising fitting into a linear mixed model a transcriptomic relationship matrix generated from a reference set of transcriptome profiles of reference subjects with and without PID to develop the PID prediction equation.

Abstract: An example system includes first servers deployed in a public cloud computing infrastructure and second servers deployed external to the public cloud computing infrastructure connected to the first servers via a layer 3 network. The first servers include first virtual routers to implement one or more virtual networks and first virtual execution elements. The first virtual execution elements execute a network controller that includes a plurality of microservices. A network device manages network routing for the second servers. The network controller is configured to exchange routing information with the network device. The network controller is configured to configure, based on the routing information, the first virtual routers to configure a virtual network of the one or more virtual networks for packetized communications among the first virtual execution elements executing on the first servers in the public cloud computing infrastructure and the second servers.

Abstract: Systems and methods of extracting an isosurface wherein points on the isosurface have a constant value. The method includes dividing a volume into a grid of voxels The method includes identifying intersecting edges in the voxels, wherein the intersecting edges intersect the isosurface. The method includes generating patches for the intersecting edges and tessellating the patches and generating a grid of tessellated vertices. The method includes determining intersection points of the tessellated vertices with the isosurface and moving the intersected vertices to form a finer approximation of the isosurface.

Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related toxi

Abstract: A lighting unit is described comprising: a microcontroller; and a near field communication (NFC)-enabled embedded device comprising NFC shared memory configured to be written to by both an external NFC reader/writer using near field communication and the microcontroller and configured to enable an operation of the lighting unit to be both monitored and controlled using NFC.

Abstract: A lighting unit having a microcontroller; and a near field communication (NFC)-enabled embedded device comprising NFC shared memory configured to be written to by both an external NFC reader/writer using near field communication and the microcontroller and configured to enable an operation of the lighting unit to be both monitored and controlled using NFC. In this manner, the operation of a lighting unit may be monitored using NFC and controlled by using one of two approaches, such as via a microcontroller within the lighting unit and/or a near field communication, NFC, via the NFC-enabled embedded device; wherein the microcontroller is configured to manage a communication protocol to facilitate communications between the lighting unit and at least one other NFC-enabled device.

Abstract: A lighting unit having a microcontroller; and a near field communication (NFC)-enabled embedded device comprising NFC shared memory configured to be written to by both an external NFC reader/writer using near field communication and the microcontroller and configured to enable an operation of the lighting unit to be both monitored and controlled using NFC. In this manner, the operation of a lighting unit may be monitored using NFC and controlled by using one of two approaches, such as via a microcontroller within the lighting unit and/or a near field communication, NFC, via the NFC-enabled embedded device; wherein the microcontroller is configured to manage a communication protocol to facilitate communications between the lighting unit and at least one other NFC-enabled device.

Abstract: A lighting unit is described comprising: a microcontroller; and a near field communication (NFC)-enabled embedded device comprising NFC shared memory configured to be written to by both an external NFC reader/writer using near field communication and the microcontroller and configured to enable an operation of the lighting unit to be both monitored and controlled using NFC.

Abstract: A lighting unit is described comprising: a microcontroller; and a near field communication (NFC)-enabled embedded device comprising NFC shared memory configured to be written to by both an external NFC reader/writer using near field communication and the microcontroller and configured to enable an operation of the lighting unit to be both monitored and controlled using NFC. In this manner, the operation of a lighting unit may be monitored using NFC and controlled by using one of two approaches, such as via a microcontroller within the lighting unit and/or a near field communication, NFC, via the NFC-enabled embedded device.

Abstract: Systems and methods of extracting an isosurface wherein points on the isosurface have a constant value. The method includes dividing a volume into a grid of voxels The method includes identifying intersecting edges in the voxels, wherein the intersecting edges intersect the isosurface. The method includes generating patches for the intersecting edges and tessellating the patches and generating a grid of tessellated vertices. The method includes determining intersection points of the tessellated vertices with the isosurface and moving the intersected vertices to form a finer approximation of the isosurface.

Abstract: Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample via a primer extension reaction directed a highly conserved nucleic acid sequences in the microorganisms under test. The biological sample is typically immobilised on a solid substrate at a first location before being transferred to a second location for analysis using the DMP. The methods and apparatus of the invention are particularly suited to diagnosis of the presence of infectious pathogens in the biological sample, for example for diagnosis of sexually transmitted infection.

Abstract: The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.

Abstract: The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol; (c) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising combinations according to the invention, and methods of treatment using the same.

Abstract: A first aspect of the invention relates to a method of treating a proliferative disorder in a subject, said method comprising administering to the subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) seliciclib; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle, wherein said i first treatment cycle comprises: (a) administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 to 5 consecutive days for 2 weeks, starting on day d, where d is the first day of treatment with sapacitabine, or the metabolite thereof, in said first treatment cycle; and (b) optionally administering a therapeutically effective amount of seliciclib for 3 to 5 consecutive days for 2 weeks, starting on day (d?1) relative to the administration of sapacitabine or the metabolite thereof, in said first treatment cycle; followed by a rest period of at least 2 weeks, or until treatment-related to

Abstract: A method for producing a solder joint between at least one base part (2) and at least one first component (3) includes the following steps: providing the base part (2); partially blasting a surface of the base part (2) using a SACO blasting agent, the blasting material (50) of which has a silicate coating (52), in such a way that a SACO-blasted region (20) and a non-blasted positioning region (40) are present; and soldering the at least first component (3) onto the non-blasted positioning region (40), wherein the SACO-blasted region (20) acts as a solder resist.

Abstract: A method for rendering a particle-based fluid surface includes generating a depth image of a plurality of particles which form a fluid surface, and smoothing the depth image to generate a smoothed depth image. From the smoothed depth image, a smoothed surface position and a smoothed surface normal for each of a plurality of pixels included within the smoothed depth image is determined, and a shaded surface of the fluid is rendered as a function of the smoothed surface positions and the smoothed surface normals.

Abstract: The invention relates to a method for producing a solder joint between at least one base part (2) and at least one first component (3), comprising the following steps: providing the base part (2); partially blasting a surface of the base part (2) using a SACO blasting agent, the blasting material (50) of which has a silicate coating (52), in such a way that a SACO-blasted region (20) and a non-blasted positioning region (40) are present; and soldering the at least first component (3) onto the non-blasted positioning region (40), wherein the SACO-blasted region (20) acts as a solder resist.

Abstract: A facial image enhancement system includes a deformable face tracker that provides a tracked face model from a facial video stream. Additionally, the facial image enhancement system includes a face enhancement image processing engine that uses the tracked face model to process the facial video stream, wherein an image enhancement of the facial video stream provides an enhanced facial video stream. A facial image enhancement method is also provided.

Abstract: The present invention relates to compounds of formula (I) wherein: R1 and R2 are each independently H, alkyl or haloalkyl; R3 and R4 are each independently H, alkyl, haloalkyl or aryl; R5 is alkyl or cycloalkyl or cycloalkyl-alkyl, each of which may be optionally substituted with one or more OH groups; R6 is selected from cyclopropylamino, cyclopropylmethylamino, cyclobutylamino, cyclobutylmethylamino and where one of X, Y and Z is N and the remainder are CR9; R7, R8 and each R9 are independently H, alkyl or haloalkyl, wherein at least one of R7, R8 and each R9 is other than H. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula (I), and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.